Rigel Pharmaceuticals Reports Strong Growth Across Oncology Portfolio with 44% Revenue Increase
核心洞察
Rigel Pharmaceuticals' lead product Tavalisse generated $68.5 million in sales during the first half of 2025, representing a 44% year-over-year increase.
The company's second FDA-approved drug Rezlidhia showed strong momentum with 31% year-over-year growth to $13.1 million in sales.
Rigel raised its 2025 revenue guidance to $270-$280 million from the previous expectation of $200-$210 million due to strong commercial performance.
Rigel Pharmaceuticals has demonstrated robust commercial momentum across its oncology and hematology portfolio, with the company raising its 2025 revenue guidance by approximately 35% following strong sales performance in the first half of the year.
Strong Commercial Performance Drives Revenue Growth
The company's flagship product Tavalisse (fostamatinib disodium hexahydrate) continues to serve as the primary revenue driver, generating $68.5 million in sales during the first half of 2025, representing a 44% year-over-year increase. Tavalisse, an oral spleen tyrosine kinase inhibitor, is approved by the FDA for adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment. The drug has also secured approvals in Europe, the United Kingdom, Japan, and other international markets.
Rigel's second FDA-approved product, Rezlidhia (olutasidenib), demonstrated equally impressive growth with sales increasing 31% year-over-year to $13.1 million during the first half of 2025. The drug is indicated for treating adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible IDH1 (搜索) mutation as detected by an FDA-approved test.
The company has expanded its portfolio through strategic acquisitions, adding Gavreto (pralsetinib) after acquiring commercial rights from Blueprint Medicines, now part of Sanofi, in 2024. Rigel began recognizing Gavreto sales from June 2024, with incremental sales from the drug contributing to the company's top-line growth during the first half of 2025.
Revised Financial Guidance Reflects Commercial Success
Based on the strong sales performance across its marketed products, Rigel increased its total revenue guidance for 2025 to $270-$280 million, compared with the previous expectation of $200-$210 million. This represents a significant upward revision of approximately 35% at the midpoint.
Pipeline Development and Strategic Partnerships
Beyond its approved products, Rigel is advancing its pipeline with encouraging progress. The company is currently conducting a Phase Ib study evaluating R289, a novel dual IRAK1 (搜索) and IRAK4 (搜索) inhibitor, in patients with lower-risk myelodysplastic syndrome (MDS). Enrollment in the dose escalation portion of the study has been completed, with Rigel planning to initiate the dose expansion phase in the second half of 2025. Updated dose escalation data is expected later this year.
Rigel has established strategic partnerships to expand its global reach, including an exclusive license agreement with Dr. Reddy's to develop and commercialize Rezlidhia across multiple territories including Latin America, South Africa, India, Southeast Asia, North Africa, Australia, and New Zealand. Under this agreement, Rigel is entitled to receive potential regulatory and commercial milestone payments.
The company is also exploring expanded applications for Rezlidhia beyond its current indication, investigating its use in other cancers with IDH1 (搜索) mutations, such as recurrent glioma.
Competitive Landscape Considerations
Despite strong performance, Rigel faces emerging competition in its target markets. The FDA recently approved Sanofi's Wayrilz (rilzabrutinib), a novel BTK (搜索) inhibitor for persistent or chronic ITP in adult patients who have had insufficient response to previous treatment. While Tavalisse and Wayrilz operate through different mechanisms, the launch of Wayrilz by a large pharmaceutical company like Sanofi presents a potential competitive threat.
Additionally, Gavreto faces competition from Eli Lilly's Retevmo (selpercatinib), which is approved for certain cancer indications including non-small cell lung cancer and thyroid cancer. Eli Lilly acquired Retevmo through its acquisition of Loxo Oncology (搜索).